06855.HK
Ascentage Pharma Group International
HKSE · Healthcare · Biotechnology · CN
HKD 35.00
+1.74%Aug 19, 2026, 23:00 UTC
Ascentage Pharma appointed Dr. Faical Miyara as Chief Business Officer.
Source:Aug 19, 2026, 23:00 UTC
Ascentage Pharma reported interim unaudited financial results for the first half of 2026, with revenue increasing 29% year-over-year to US$44.5 million (RMB302.2 million), primarily due to increased product sales.
Aug 2, 2026, 23:46 UTC
Ascentage Pharma appointed Faiçal Miyara as Chief Business Development Officer and Jim Ziegler as Chief Commercial Operations Officer, both reporting to Chairman and CEO Yang Dajun.
Jul 19, 2026, 13:12 UTC
Ascentage Pharma Group files a shelf registration statement with the U.S. SEC for an at-the-market offering of up to $200 million in American Depositary Shares.
May 31, 2026, 23:30 UTC
Ascentage Pharma presented its first dataset on MDM2-p53 inhibitor alrizomadlin (APG-115) in pediatric solid tumors at the ASCO 2026 Annual Meeting.